Cell and Gene Outsourcing

  1. FDA's 483 Playbook: What It Means For Pharma Outsourcing — And What It Doesn't Address 3/17/2026

    For those involved in outsourcing, the new FDA draft guidance regarding FDA Form 483 observations reshapes the accountability framework. The public comment period ends May 8.

  2. How To Select The Right Fill-Finish CDMO For Phase I–II 3/16/2026

    Early‑phase programs require flexible, technically aligned fill‑finish partners. Mid‑sized CDMOs offer a balance of agility, infrastructure, and regulatory maturity suited to Phase I–II needs.

  3. Scientific Staffing 3/16/2026

    A customizable scientific‑insourcing model delivers flexible onsite staffing, boosts lab capacity, reduces hiring burdens, and supports routine scientific work with trained professionals.

  4. Pharma's Guide To Navigating Complex Impurity Compliance And Profiling 3/16/2026

    Evolving regulations require proactive impurity control using trace‑level detection, solid risk assessment, advanced analytics, and ongoing monitoring to prevent compliance issues.

  5. Technical Field Services 3/16/2026

    A flexible technical field‑services program offers multi‑vendor laboratory instrument support, facility services, relocations, and environmental qualifications to optimize operations, reduce risk, and maintain compliance.

  6. Solving The Scientific Talent Gap With Flexible Insourcing 3/16/2026

    High turnover in scientific labs drives hidden costs—from lost expertise to productivity gaps and compliance risks. Flexible insourcing offers a strategic way to stabilize operations.

  7. Accelerating Technology Diffusion In Cell And Gene Therapy 3/11/2026

    Unlike most other drugs, advanced therapies require complex, purpose-built supply chain networks. Making them requires cross-sector collaboration.

  8. Precision Control In Animal‑Free Raw Materials 3/10/2026

    Animal‑free raw materials offer adjustable attributes, controlled manufacturing, and consistent nutrient profiles, ensuring reliable performance and customizable solutions across multiple production processes.

  9. Consistency Engineered For Animal‑Free Bioprocessing 3/10/2026

    Animal‑free soy‑based materials provide consistent molecular weight profiles, stable mineral levels, and controlled manufacturing to ensure reliable, reproducible bioprocessing performance.

  10. Consistency You Can Trust in Animal‑Free Raw Materials 3/10/2026

    Animal‑free raw materials ensure reliable bioprocessing through stable molecular weight profiles, consistent mineral levels, and controlled manufacturing for dependable lot‑to‑lot performance.